Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2025-12-24 @ 9:56 PM
NCT ID:
NCT00695032
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of a solid tumor
* Any location allowed
* Metastatic disease allowed
* Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy
PATIENT CHARACTERISTICS:
Inclusion criteria:
* Life expectancy \> 3 months
* Creatinine clearance ≥ 60 mL/min
* Must be available for follow up
* Not pregnant or nursing
* Not under guardianship or in prison
Exclusion criteria:
* Prior drug-related nephrotoxicity
* Acute, uncontrolled urinary infection or \> 48-hours
* Pre-existing hemorrhagic cystitis
* Weak bladder
* Bilateral obstruction of urinary tract
* Insufficient, severe bone marrow hypoplasia
* Cardiorespiratory condition contraindicating hyperhydration
* Hearing impairment
* Hypersensitivity to cisplatin or products containing platinum
* Major psychiatric condition (severe depression, psychosis, dementia)
PRIOR CONCURRENT THERAPY:
* No prior yellow fever vaccine, live attenuated vaccine, or phenytoin
* No concurrent participation in another biomedical study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00695032
Study Brief:
Protocol Section:
NCT00695032